On May 7, 2025, HC Wainwright & Co. analyst Raghuram Selvaraju released an updated analyst report on Axsome Therapeutics (AXSM, Financial). The investment firm maintained its 'Buy' rating on the stock, indicating a positive outlook for the company's future performance. Despite the maintained rating, there was a notable change in the price target for the stock.
The price target for Axsome Therapeutics (AXSM, Financial) was lowered by HC Wainwright & Co. Analyst Raghuram Selvaraju adjusted the target from the prior value of USD 200.00 down to USD 180.00. This adjustment marks a 10% decrease in the expected price target for the stock. The updated price target reflects a cautious approach while maintaining confidence in Axsome Therapeutics' prospects.
Axsome Therapeutics (AXSM, Financial), a notable player in the biopharmaceutical industry, continues to hold a 'Buy' rating, signifying that analysts believe it offers potential investment value. Investors and stakeholders are advised to take note of the revised price target while considering the encouragement from the maintained 'Buy' stance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Axsome Therapeutics Inc (AXSM, Financial) is $177.53 with a high estimate of $210.00 and a low estimate of $143.00. The average target implies an upside of 58.28% from the current price of $112.16. More detailed estimate data can be found on the Axsome Therapeutics Inc (AXSM) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Axsome Therapeutics Inc's (AXSM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Axsome Therapeutics Inc (AXSM, Financial) in one year is $262.18, suggesting a upside of 133.76% from the current price of $112.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Axsome Therapeutics Inc (AXSM) Summary page.
